Sweden has been in the forefront of drug development for decades, not least due to the heritage from Pharmacia and Astra. Today, this legacy manifests itself through the presence of a strong, life science eco-system with a pool of competent professionals all across the value chain from world-leading academic pre-clinical and clinical research to manufacturing.
The Swedish Drug Development Pipeline 2015
This report provides facts and figures about the current Swedish drug development pipeline for drugs intended for use in humans including the status and progress of pipeline compounds, projects and their characteristics. The report covers 123 Swedish drug developing companies, of which 58 companies collectively run 107 projects in clinical phases. Oncology is the dominating indication area with 38 projects.